ClinicalTrials.gg

Program

risvutatug rezetecan

Also written as “HS-20093”, “HS-20093 for Injection” and “Risvutatug rezetecan (Ris-Rez)”.

In GlaxoSmithKline’s pipeline, ADC targeting B7-H3. Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung · Osteosarcoma · Neoplasms · Prostatic Neoplasms, led by 3 companies.

Furthest: phase 3, since Jul 6, 202430 company-led studies, 26 open or runningLicense: Hansoh → GSK, Dec 2023Next primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group2117 open or runningphase 3since Jul 6, 2024Feb 18, 2022Dec 30, 2026phase 1 · NCT06699576
GlaxoSmithKline88 open or runningphase 3since Jul 30, 2025Mar 3, 2022Nov 5, 2027phase 3 · NCT07099898
Jiangsu HengRui Medicine11 open or runningphase 2since Nov 13, 2025Nov 13, 2025Dec 2028phase 2 · NCT07230106
  • Named in GlaxoSmithKline’s own pipeline as risvutatug rezetecan GSK5764227, phase 3, as of Sep 30, 2026 (source).
  • Named in Hansoh Pharmaceutical Group’s own pipeline as HS-20093 (B7-H3 ADC), phase 3, as of Aug 26, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

  • LicenseGSK licensed it from Hansoh, for everywhere outside mainland China, Hong Kong, Macau and Taiwan.Announced Dec 20, 2023 · Source: GSK, Dec 20, 2023

How Jiangsu HengRui Medicine relates to it is not in the registry or these sources.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. Dates ahead are the sponsors’ estimates.

Not listed one by one: 17 earlier studies, Feb 18, 2022 to Jul 30, 2025.

  1. Dec 20, 2023GSK licensed it from HansohLicenseEverywhere outside mainland China, Hong Kong, Macau and Taiwan · announced · GSK
  2. Aug 4, 2025Phase 1 study in Advanced Prostate CancerHansoh Pharmaceutical Group · NCT07115446 · 63 planned · China
  3. Sep 9, 2025Phase 1 study in Advanced Solid TumorsHansoh Pharmaceutical Group · NCT07186452 · 18 planned · China
  4. Nov 13, 2025Jiangsu HengRui Medicine’s first study: phase 2 study in Prostatic NeoplasmsNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT07230106 · 218 planned · China
  5. Dec 2, 2025Phase 1 study in NeoplasmsGlaxoSmithKline · NCT07277270 · 83 planned · United States, Australia, Canada and more
  6. Jan 15, 2026Phase 1 study in Advanced Gastric and Gastroesophageal Junction AdenocarcinomaHansoh Pharmaceutical Group · NCT07462923 · 40 enrolled · China
  7. Mar 6, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungHansoh Pharmaceutical Group · NCT07464327 · 450 planned
  8. May 11, 20262 phase 2 studiesGlaxoSmithKline · NCT07602777, NCT07602855
  9. May 26, 2026Phase 3 study in Esophageal Squamous Cell CarcinomaHansoh Pharmaceutical Group · NCT07621601 · 494 planned
  10. Aug 13, 2026Phase 1 study in Small Cell Lung CarcinomaHansoh Pharmaceutical Group · NCT07892625 · 338 planned
  11. Aug 13, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungHansoh Pharmaceutical Group · NCT07824882 · 76 planned · China
  12. Aug 28, 2026Phase 3 study in Prostatic NeoplasmsGlaxoSmithKline · NCT07802704 · 684 planned · Australia, Canada, Japan and more
  13. Sep 25, 2026Primary completion moved from 2026-07-13 to 2028-02-14Date moved laterphase 1 · +19 months · NCT07277270
  14. Oct 19, 2026Primary completion moved from 2028-01-10 to 2029-01-09Date moved laterphase 2 · +12 months · NCT06885034
  15. Oct 20, 2026Phase 1 study in Carcinoma, Non-Small-Cell LungHansoh Pharmaceutical Group · NCT07899086 · 102 planned

Ahead

  1. Dec 30, 2026Primary completion: phase 1 study in OsteosarcomaHansoh Pharmaceutical Group · NCT06699576
  2. Dec 31, 2026Primary completion: phase 1 study in Advanced Gastric and Gastroesophageal Junction AdenocarcinomaHansoh Pharmaceutical Group · NCT07462923
  3. Nov 5, 2027Primary completion: phase 2 study in SarcomaGlaxoSmithKline · NCT07602777
  4. Nov 5, 2027Primary completion: phase 3 study in Lung NeoplasmsGlaxoSmithKline · NCT07099898

TargetBeta

“ADC targeting B7-H3”the company's pipeline, read by Claude · source
“B7-H3 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of risvutatug, a humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the T-cell checkpoint ligand B7-homologue 3 (B7-H3, CD276) covalently ”NCIt, by rule

Other programs on CD276

ProgramCompanyFurthest phaseStudies
ifinatamab deruxtecanMerckphase 316
tambotatug pelitecanMediLink Therapeutics (Suzhou)phase 313
Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043CSPC Pharmaceutical Groupphase 35
Anti-B7-H3 Antibody-drug Conjugate MHB088CruleMinghui Pharmaceuticalphase 34
Elfetabart DrozuntecanruleBioNTechphase 33
Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101ruletj-biopharma-co-ltdphase 33
Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01ruleradiopharm-theranostics-ltdphase 21
Autologous Anti-B7-H3 CAR T-cells BCB-276rulebrainchild-bio-incphase 21
Anti-B7-H3/CD28 Bispecific Antibody XmAb808ruleXencorphase 12
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034ruleideaya-biosciencesphase 11
Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001ruleneok-bio-incphase 11
HLX316Fosun Pharmaphase 11

Studies

All 30 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07899086Carcinoma, Non-Small-Cell Lung1Not yet recruitingHansoh Pharmaceutical GroupDec 31, 2027102
NCT07802704Prostatic Neoplasms · Australia, Canada, Japan and more3RecruitingGlaxoSmithKlineDec 5, 2029684
NCT07892625Small Cell Lung Carcinoma1Not yet recruitingHansoh Pharmaceutical GroupSep 15, 2028338
NCT07824882Carcinoma, Non-Small-Cell Lung · China2RecruitingHansoh Pharmaceutical GroupMar 30, 202876
NCT07621601Esophageal Squamous Cell Carcinoma3Not yet recruitingHansoh Pharmaceutical GroupDec 31, 2030494
NCT07602855Lung Neoplasms · United States, Japan2RecruitingGlaxoSmithKlineJun 22, 2029184
NCT07602777Sarcoma · United States, Canada, France and more2RecruitingGlaxoSmithKlineNov 5, 202764
NCT07464327Carcinoma, Non-Small-Cell Lung3Not yet recruitingHansoh Pharmaceutical GroupDec 31, 2028450
NCT07462923Advanced Gastric and Gastroesophageal Junction Adenocarcinoma · China1Active, not recruitingHansoh Pharmaceutical GroupDec 31, 202640
NCT07277270Neoplasms · United States, Australia, Canada and more1RecruitingGlaxoSmithKlineFeb 14, 202883
NCT07230106Prostatic Neoplasms · China2RecruitingJiangsu HengRui MedicineDec 2028218
NCT07186452Advanced Solid Tumors · China1RecruitingHansoh Pharmaceutical GroupJul 31, 202618
NCT07115446Advanced Prostate Cancer · China1RecruitingHansoh Pharmaceutical GroupDec 202763
NCT07099898Lung Neoplasms · United States, Argentina, Australia and more3RecruitingGlaxoSmithKlineNov 5, 2027420
NCT07063407Extensive Stage Small Cell Lung Cancer (ES-SCLC)1Not yet recruitingHansoh Pharmaceutical GroupApr 30, 202650
NCT06935409Osteosarcoma · China3CompletedHansoh Pharmaceutical GroupJun 17, 2026122
NCT06885034Gastrointestinal Neoplasms · United States, Australia, Belgium and more2RecruitingGlaxoSmithKlineJan 9, 2029346
NCT06825624Colorectal Neoplasms · China1RecruitingHansoh Pharmaceutical GroupOct 31, 2026560
NCT06699576Osteosarcoma1Not yet recruitingHansoh Pharmaceutical GroupDec 30, 2026448
NCT06551142Neoplasms · United States, Argentina, Canada and more1RecruitingGlaxoSmithKlineOct 16, 2028845
NCT06526624Small Cell Lung Carcinoma3Not yet recruitingHansoh Pharmaceutical GroupNov 30, 2027406
NCT06498479Small Cell Lung Carcinoma · China3CompletedHansoh Pharmaceutical GroupAug 20, 2026461
NCT06332170Advanced Solid Tumor · China1RecruitingHansoh Pharmaceutical GroupMay 30, 2026610
NCT06112704Esophageal Neoplasms · China2RecruitingHansoh Pharmaceutical GroupJul 31, 2026220
NCT06052423Extensive Stage Small Cell Lung Cancer (ES-SCLC)2WithdrawnHansoh Pharmaceutical GroupJun 30, 20250
NCT06007729Squamous Cell Carcinoma of Head and Neck · China2RecruitingHansoh Pharmaceutical GroupDec 12, 2025170
NCT06001255Metastasis Castration Resistant Prostate Cancer(mCRPC) · China2RecruitingHansoh Pharmaceutical GroupDec 31, 2024120
NCT05830123Osteosarcoma · China2RecruitingHansoh Pharmaceutical GroupDec 31, 2025170
NCT05277051Neoplasms · United States, Australia, Canada and more1Active, not recruitingGlaxoSmithKlineJun 30, 2026152
NCT05276609Advanced Solid Tumor · China1UNKNOWNHansoh Pharmaceutical GroupDec 31, 2023177

How it is read

Names in the registry

  • “HS-20093”, 15 entries
  • “HS-20093 for Injection”, 4 entries
  • “Risvutatug rezetecan (Ris-Rez)”, 2 entries
  • “GSK5764227”, 2 entries
  • “Ris-Rez”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.